|1.||Palumbo, Antonio: 39 articles (12/2015 - 08/2002)|
|2.||Sanchorawala, Vaishali: 25 articles (11/2015 - 06/2002)|
|3.||Boccadoro, Mario: 24 articles (12/2015 - 08/2002)|
|4.||Eggermont, Alexander M M: 24 articles (02/2015 - 01/2003)|
|5.||Seldin, David C: 23 articles (11/2015 - 06/2002)|
|6.||Tyler, Douglas S: 21 articles (02/2015 - 08/2004)|
|7.||Petrucci, Maria Teresa: 18 articles (12/2015 - 01/2002)|
|8.||Anderson, Kenneth C: 18 articles (04/2015 - 07/2002)|
|9.||Dimopoulos, Meletios A: 18 articles (04/2015 - 10/2003)|
|10.||Bringhen, Sara: 18 articles (10/2014 - 08/2002)|
01/01/1992 - "These results indicate that although VBAD is effective in at least one third of patients with advanced multiple myeloma resistant to melphalan, its impact on survival is limited."
03/01/1989 - "The response rate and the low toxicity observed in this group of patients are encouraging and suggest that intermediate-dose intravenous melphalan is an effective and safe second line treatment for patients with multiple myeloma not responding to conventional treatment."
06/01/2013 - "Here, we evaluated the efficacy of melphalan-flufenamide (mel-flufen), a novel dipeptide prodrug of melphalan in multiple myeloma. "
09/01/2010 - "200 mg/m(2) melphalan--the gold standard for multiple myeloma."
04/01/1996 - "Melphalan has brought the first improvement in the therapy of multiple myeloma at the beginning of the sixties. "
06/01/1998 - "The remarkable histologic response to perfusion in several pretreated patients, especially after application of high-dose TNF and melphalan, suggests that this modality is very effective in tumor killing."
12/01/1990 - "tumor nodules of MOPC-315 tumor bearers following low-dose L-PAM therapy most likely exploit a CTL-type lytic mechanism to eradicate at least part of the large tumor burden not eliminated by the direct antitumor effects of the drug."
01/01/1988 - "Highly variable renal clearance involving active secretion may contribute in part to large interpatient differences in the total plasma clearance of melphalan in patients with cancer."
06/01/1986 - "When L-PAM response is related to nuclear grade, a marker of tumor differentiation, there is a highly significant improvement in DFS (less than .001), distant DFS (.001), and survival (.004) through 10 years of observation for all patients with tumors classified as nuclear grade poor (poorly differentiated), regardless of age and nodal status. "
04/22/1992 - "Thus, the therapeutic effectiveness of L-PAM TuB spleen cells in ACIT may be improved by aggressive depletion of CD4+ T-cells, suggesting that a low dose of L-PAM, which leads to the acquisition of potent splenic-tumor-eradicating immunity in BALB/c mice bearing a large MOPC-315 tumor, does not eliminate completely (or possibly not at all) the inhibitory activity of CD4+ T-cells. "
|3.||Melanoma (Melanoma, Malignant)
03/01/1975 - "The addition of heat to regional perfusion with melphalan has dramatically improved the objective response of melanoma. "
11/01/2012 - "Isolated limb infusion with melphalan (ILI-M) corrected for ideal body weight (IBW) is a well-tolerated treatment for patients with in-transit extremity melanoma with an approximate 29 % complete response (CR) rate. "
03/20/2011 - "Isolated limb infusion (ILI) with melphalan (M-ILI) dosing corrected for ideal body weight (IBW) is a well-tolerated treatment for patients with in-transit melanoma with a 29% complete response rate. "
10/15/2009 - "Isolated limb infusion with melphalan is a well-tolerated treatment for patients with in-transit extremity melanoma with an approximately 30% complete response (CR) rate. "
08/01/2006 - "We attempted a novel approach in this condition using a technique of intra-arterial limb infusion with cytotoxic agent Melphalan (ILI) which has been proven beneficial in management of localised malignant melanoma. "
03/01/2014 - "Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement."
01/01/2010 - "Aggressive treatment with high-dose i.v. melphalan followed by auto-SCT (HDM/SCT) is effective in inducing hematological and clinical remissions, and in extending survival in AL amyloidosis. "
11/01/2013 - "We designed a trial using two sequential cycles of modified high-dose melphalan at 100 mg/m(2) and autologous SCT (mHDM/SCT) in AL amyloidosis (light-chain amyloidosis, AL), AL with myeloma (ALM) and host-based high-risk myeloma (hM) patients through SWOG-0115. "
11/01/2013 - "Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115."
12/15/2012 - "The study group included all 74 patients with AL amyloidosis who underwent high-dose melphalan treatment supported by autologous SCT since the beginning of the Mayo Clinic's SCT program until prior to August 2001. "
|5.||Sarcoma (Soft Tissue Sarcoma)
03/15/1997 - "The combination of high dose rTNF-alpha and melphalan given via ILP appears to be effective in patients with advanced soft tissue sarcoma confined to the limb, achieving a high response rate and limb preservation."
05/01/2001 - "HILP with melphalan is a safe and effective treatment option for selected patients with locally advanced and unresectable extremity sarcomas. "
03/15/1997 - "The purpose of the current study was to assess the role of rTNF-alpha and melphalan administered via ILP in patients with soft tissue sarcoma. "
02/15/2015 - "The addition of oncolytic vaccinia virus to existing TNF-α/melphalan-based ILP strategies results in survival advantage in an immunocompetent rat model of advanced extremity sarcoma. "
02/15/2015 - "An orthotopic model of advanced extremity sarcoma was used to evaluate survival of animals after ILP with combinations of TNF-α, melphalan and GLV-1h68. "
|4.||Etoposide (VP 16)
|5.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|1.||Drug Therapy (Chemotherapy)
|2.||Stem Cell Transplantation
|4.||Combination Drug Therapy (Combination Chemotherapy)
|5.||Bone Marrow Transplantation (Transplantation, Bone Marrow)